SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is trending due to speculation around a potential ETF approval and general excitement for altcoin season, with the community actively discussing institutional investment and real-world use cases. Some investors believe the token is undervalued, while others caution against over-optimism given past performance, dilution and the need for regulatory clarity. Despite differing opinions, there's a consensus that HBAR is showing strength, and an ETF could open the door to institutional investments.

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

TPST is trending amid ongoing speculation of a potential acquisition, with community members highlighting its promising oncology assets and Roche's potential interest. Discussions revolve around Roche's existing collaboration with Tempest and the strategic value of acquiring TPST's liver cancer therapy. Some traders express concerns about cash runway and timing, while others point to technical indicators and potential buyout scenarios, anticipating news soon.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following news of its acquisition of Arduino, a move seen as expanding its reach in AI and robotics. The community is discussing the potential benefits of this acquisition and how it may position the company against competitors. Some traders are closely watching technical indicators and option flow for potential upside.

Perimeter Solutions, Inc. engages in the provision of global solutions for fire safety and specialty products industries. It operates through the Fire Safety and Specialty Products segments. The Fire Safety segment specializes in the formulation, manufacture, and sale of fire retardants and firefighting foams that assist in combating various types of fires, including wildland, structural, flammable liquids, and others. It also offers specialized equipment and services, which include airbase retardant storage, mixing, and delivery equipment, mobile retardant bases, retardant ground application units, mobile foam equipment, and others The Specialty Products segment produces and sells phosphorus pentasulfide (P2S5), primarily used in the preparation of lubricant additives, including a family of compounds called zinc dialkyldithiophosphates (ZDDP) that provide critical anti-wear protection to engine components. The company was founded in 2018 and is headquartered in Clayton, MO.

Perimeter Solutions Inc.

Perimeter Solutions SA

Perimeter Solutions ($PRM) is trending due to a recent USDA agreement and positive analyst ratings, with UBS maintaining a Buy rating and raising the price target. The community is discussing the company's strong financials, potential for long-term growth in fire safety products, and a possible monopoly on USDA-quality fire retardant. Some traders are noting bullish sweep call activity and anticipating upcoming earnings.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the company's L- and S-band frequencies are now part of the official global 3GPP standard, potentially enabling direct-to-device satellite connectivity on billions of existing phones; the community is discussing the significance of this standardization and its impact on scalability and partnerships with mobile network operators. Bullish sentiment surrounds the implications of this milestone, with some speculating about future partnerships and government contracts, while bears express concerns about dilution and valuation.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending as analysts discuss its bullish momentum and potential for further gains, particularly noting the strong buying opportunity around the "Blue Box" area. Community discussions revolve around Elliott Wave analysis, identifying key support levels and potential paths for continued upside. Broader market commentary suggests a positive outlook for European equities, with some analysts pointing to potential outperformance compared to U.S. markets.

Direxion Shares ETF Trust - Direxion Daily Gold Miners Index Bear -2X Shares

Direxion Daily Gold Miners Index Bear 2X Shares

Amidst fluctuating gold prices, DUST is trending as traders discuss potential corrections in the overbought gold and miners sectors. Community members are weighing in on key psychological levels for gold, like $4000, and whether a significant pullback is imminent. Some traders are using DUST as a hedge against long gold positions, while others debate the merits and risks of leveraged inverse ETFs.

BlackRock Institutional Trust Company N.A. - iShares MSCI Japan ETF

iShares MSCI Japan ETF

EWJ is trending amid discussions of potential shifts in Japanese monetary policy and its impact on the yen. Community members are weighing the ETF's potential amid global economic uncertainty, with some noting technical breakout patterns. Broader market factors, such as inflation and central bank decisions in Japan, are also driving interest.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss its potential amid mixed sentiment, influenced by a recent analyst downgrade and news of layoffs. Despite concerns about EV demand and cash burn, the community is also focused on the company's long-term prospects, including the upcoming R2 vehicle and its relationship with Amazon. Technical analysis suggests a possible breakout, with some traders eyeing potential upside based on future production and profitability.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as retail traders speculate on a potential recovery following Q2 earnings, with community members actively discussing Medicare Advantage and Optum segments. Anticipation is building for the upcoming earnings call, where investors are keen to hear about cost pressures, margin recovery, and forward guidance. Community members are weighing the potential impact of MLR and guidance for 2026.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vera Therapeutics stock sinks following competitor’s successful trial

Investing.com -- Shares of  Vera Therapeutics  (NASDAQ:VERA) tumbled by 33% in premarket trading today after a Japanese competitor, Otsuka, reported positive results from a Phase 3 trial of a competing kidney disease therapy. Otsuka’s announcement indicated that its drug, sibeprenlimab, achieved a 51.2% reduction in proteinuria in the treatment of immunoglobulin A nephropathy (IgAN), surpassing the results from Vera’s own candidate, atacicept.

Shares of Vera Therapeutics, Inc. (VERA) were in the spotlight on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-refinancing-existing-oxford-debt">announced</a> that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner, Oxford Finance LLC.The new credit facility will replace Vera’s existing $50 million credit facility. The initial funding of the new credit facility will be in a principal amount of $75 million and is expected to occur on June 4, 2025, the company said.The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.Vera Therapeutics is looking to submit a Biologics License Application to the U.S. Food and Drug Administration in the fourth quarter of this year for Atacicept. The company is looking forward to the potential commercialization of the investigational drug for the treatment of immunoglobulin A nephropathy (IgAN) in adults.IgA nephropathy, also known as Berger's disease, is a kidney disease where antibodies build up in the kidneys, causing inflammation and damage.Vera on Monday said that Atacicept achieved a 46% reduction from baseline in protein levels in the urine of 431 adults with IgA nephropathy being evaluated in a late-stage trial.VERA stock closed 67% higher on Monday on the news.On Stocktwits, retail sentiment around VERA stayed unmoved within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_03_at_8_05_39_AM_png_bf7adee158.webp" alt="VERA's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 3, 2025 | Source: Stocktwits" width="624" height="68"><figcaption>VERA's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 3, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user praised the company’s decisions.<stembedurl>https://stocktwits.com/US_Bull/message/616604119</stembedurl>Another expects the stock will hit $40 soon.<stembedurl>https://stocktwits.com/tomf95/message/616602882</stembedurl><a href="https://stocktwits.com/symbol/VERA">VERA stock</a> is down by 25% this year and by about 21% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/weride-partners-with-renault-for-autonomous-shuttle-service-at-the-french-open/chkr56IRbvO">WeRide Partners With Renault To Provide Autonomous Shuttle At The French Open, But Retail’s Not Excited</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40

The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.

Equity

The new credit facility features a lower interest rate, increasing capital availability and financial flexibility, the company stated.


Commit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Options

Investors eyeing a purchase of Vera Therapeutics Inc (VERA) shares, but cautious about paying the going market price of 38.14/share, might benefit from considering selling puts among the...

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

72-week data of atacicept in IgAN accepted as a best-ranked abstract Analysis of impact of atacicept on hematuria in IgAN accepted as a focused oral presentation BRISBANE, Calif., April 02...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA Research Report), Tyra Bioscience (TYRA...

Vera Therapeutics reports FY23 EPS ($2.25) vs ($3.35) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and...

Vera Therapeutics (VERA, $44.19) Aroon Indicator entered an Uptrend on March 12, 2024.

Over the last three days, A.I.dvisor has detected that VERA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Vera Therapeutics (VERA, $43.15) Aroon Indicator entered an Uptrend on March 11, 2024.

Vera Therapeutics (VERA, $44.3) Aroon Indicator entered an Uptrend on March 08, 2024.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

VERA
Vera Therapeutics Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VERA News

VERAVera Therapeutics Inc - Ordinary Shares - Class A